anyone watching?, page-6

new methadose sales and co. info MethaDose™, the dispensing product deployed in more than 60 sites in Australia and attracting
growing international interest, continues to be deployed in Australia. This week Argus has
received additional orders for MethaDose™ from a hospital in Victoria which will use the product
as part of their provision of services to Corrections Victoria. The deal is worth more than $80,000.

The use of biometrics to provide positive assurance of identification continues to grow in
acceptance in the market place, particularly where customers are able to readily identify business
improvements and benefits. MethaDose™ clearly prevents the likelihood of overdosing, misdosing
and fraudulent acquisition of restricted and/or dangerous drugs while streamlining the
dispensing process. Iris recognition offers a degree of accuracy better than DNA matching and is
a non-contact technology. When this is combined with robust dispensing software the customer is
delivered a unique application which improves their business flow and processes. For example, a
300 patient Sydney clinic reduced their weekly man-hour overhead from 140 hours to 11 using
iris based MethaDose™.

The market is increasingly recognizing the strength of this application which has harnessed the
unique benefits of biometric identification technology. Argus sees growth in sales of this product,
both in Australia and internationally which reflects a growing trend in the community to accept the
role biometrics can play in solving critical identification problems.